IP Library Granted Patent US 9,359,365
Granted Patent B2
US 9,359,365 · App. 14/506,429 · Granted Jun 7, 2016

Heterocyclic compounds and uses thereof

Inventors: Alfredo C. Castro (Woburn, MA); Catherine A. Evans (Somerville, MA); Somarajannair Janardanannair (Woburn, MA); Andre Lescarbeau (Somerville, MA); Tao Liu (Ashland, MA); Martin R. Tremblay (Melrose, MA)
Assignee: Infinity Pharmaceuticals, Inc.
C07D487/04C07D401/12C07D401/14C07D403/12C07D403/14C07D417/14C07D471/04C07D471/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,359,365
App. No.
14/506,429
Granted
Jun 7, 2016
Kind
B2
Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Claims (26)

1. A compound of the formula:

or a pharmaceutically acceptable form thereof, wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or a mixture of enantiomers.

2. The compound of claim 1 , wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt, enantiomer, or a mixture of enantiomers.

3. A compound of the formula:

4. A compound of the formula:

or a pharmaceutically acceptable form thereof, wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt, hydrate, or solvate.

5. The compound of claim 4 , wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt.

6. A compound of the formula:

7. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 55%.

8. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 75%.

9. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 90%.

10. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 95%.

11. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 98%.

12. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 99%.

13. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically acceptable excipients.

14. A pharmaceutical composition comprising a compound of claim 2 and one or more pharmaceutically acceptable excipients.

15. A pharmaceutical composition comprising a compound of claim 3 and one or more pharmaceutically acceptable excipients.

16. A pharmaceutical composition comprising a compound of claim 4 and one or more pharmaceutically acceptable excipients.

17. A pharmaceutical composition comprising a compound of claim 5 and one or more pharmaceutically acceptable excipients.

18. A pharmaceutical composition comprising a compound of claim 6 and one or more pharmaceutically acceptable excipients.

19. A pharmaceutical composition comprising a compound of claim 7 and one or more pharmaceutically acceptable excipients.

20. A pharmaceutical composition comprising a compound of claim 8 and one or more pharmaceutically acceptable excipients.

21. A pharmaceutical composition comprising a compound of claim 9 and one or more pharmaceutically acceptable excipients.

22. A pharmaceutical composition comprising a compound of claim 10 and one or more pharmaceutically acceptable excipients.

23. A pharmaceutical composition comprising a compound of claim 11 and one or more pharmaceutically acceptable excipients.

24. A pharmaceutical composition comprising a compound of claim 12 and one or more pharmaceutically acceptable excipients.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2024
From: INFINITY PHARMACEUTICALS, INC.
To: TWELVE THERAPEUTICS, INC.
Reel/Frame 069193/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2015
From: CASTRO, ALFREDO C.; EVANS, CATHERINE A.; JANARDANANNAIR, SOMARAJANNAIR; LESCARBEAU, ANDRE; LIU, TAO; TREMBLAY, MARTIN R.
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 035484/0044 →
Continuity (4)
Provisional Application 61887259 · Oct 4, 2013
Provisional Application 61888958 · Oct 9, 2013
Provisional Application 61938026 · Feb 10, 2014
Related Publication 20150111874A1 · Apr 23, 2015